Therapy With Hydrocortisone, Ascorbic Acid, Thamine in Patients With Sepsis
Status:
Completed
Trial end date:
2021-07-26
Target enrollment:
Participant gender:
Summary
In this study , we suggest that the use of combination of Hydrocortisone, Ascorbic Acid, and
Thiamine in patient with sepsis may decrease mortality rate and improve the outcome.
This study will be carried out at SICU of Tanta University hospitals on Patients aged from 18
to 65 years old who will be presented with sepsis that diagnosed according to the surviving
sepsis campaign 2016.
Patients who will meet the previous criteria will be enrolled in the study. The patients will
be randomized allocated into two groups by the aid of computer generated software of
randomization introduced into sealed closed envelops.
All patients will receive the conventional therapy according to the surviving sepsis campaign
2016 and The Surviving Sepsis Campaign Bundle 2018 Update.
The patients will be allocated randomly into one of the following two groups;-. Group I The
patients in this group will be managed only according to the surviving sepsis campaign 2016
and the surviving sepsis campaign bundle 2018 update.
The patients will receive 50 ml normal saline I.V within 30 mins / 6 h, 10 ml normal saline
I.V / 6 h, 5 ml normal saline I.V / 12 h.
Group II The patients will receive the conventional therapy of sepsis and combined therapy of
hydrocortisone (Solucortif® 100 mg , vial, dried powder Pfizer, Egypt) 50 mg diluted in 5 ml
normal saline IV / 6 h, ascorbic acid (VITAMIN C-®, Amp, ROTEXMEDICA, Germany, 500mg/5ml) 1.5
gm diluted in 50 ml normal saline IV within 30 min /6 h , and thiamine (Vitamin
B1-injektopas®, Ampoule, Germany, 100 mg / 2 ml) 200 mg diluted in 10 ml normal saline IV /12
h The outcome of the patients, the incidence of organ dysfunction will be assessed.
Phase:
N/A
Details
Lead Sponsor:
Tanta University
Collaborators:
Mohamed Mohi El deen Abo El yazeed Mostafa Ismail Sharaf Salah Eldeen Ibrahim Alsherif